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Laura Obici,o Osamu Ohara,p Seza Ozen,q Tamara Sarkisian,j Katie Sheils,r Nicola Wolstenholme,r
Evelien Zonneveld-Huijssoon,s Marielle E. van Gijn,s,*,‡ and Isabelle Touitouh,t,‡
BACKGROUND: Monogenic autoinflammatory diseases
are caused by pathogenic variants in genes that regulate
innate immune responses, and are characterized by ster-
ile systemic inflammatory episodes. Since symptoms can
overlap within this rapidly expanding disease category,
accurate genetic diagnosis is of the utmost importance
to initiate early inflammation-targeted treatment and
prevent clinically significant or life-threatening compli-
cations. Initial recommendations for the genetic diagno-
sis of autoinflammatory diseases were limited to a
gene-by-gene diagnosis strategy based on the Sanger
method, and restricted to the 4 prototypic recurrent
fevers (MEFV, MVK, TNFRSF1A, and NLRP3 genes).
The development of best practices guidelines integrating
critical recent discoveries has become essential.
METHODS: The preparatory steps included 2 online sur-
veys and pathogenicity annotation of newly recom-
mended genes. The current guidelines were drafted by
European Molecular Genetics Quality Network mem-
bers, then discussed by a panel of experts of the
International Society for Systemic Autoinflammatory
Diseases during a consensus meeting.
RESULTS: In these guidelines, we combine the
diagnostic strength of next-generation sequencing and
recommendations to 4 more recently identified genes
(ADA2, NOD2, PSTPIP1, and TNFAIP3), nonclassical
pathogenic genetic alterations, and atypical phenotypes.
We present a referral-based decision tree for test scope
and method (Sanger versus next-generation sequencing)
and recommend on complementary explorations for
mosaicism, copy-number variants, and gene dose. A ge-
notype table based on the 5-category variant pathogenic-
ity classification provides the clinical significance of pro-
totypic genotypes per gene and disease.
CONCLUSIONS: These guidelines will orient and assist
geneticists and health practitioners in providing up-to-
date and appropriate diagnosis to their patients.
Introduction
Patients suffering from systemic autoinflammatory dis-
eases (SAIDs) present with seemingly unprovoked in-
flammatory manifestations such as fever, serositis, skin
lesions, arthralgia/arthritis, acute abdominal pain, and
occasionally with lesions of the central nervous system
(1). Study of the hereditary recurrent fevers (HRFs), the
first identified group among monogenic SAIDs, has
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d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain; g Rheumatology Unit, Hadassah-Hebrew University Medical Center, Jerusalem,
Israel; h Department of Medical Genetics, Rare Diseases and Personalized Medicine,
Reference Center CEREMAIA, CHU Montpellier, University of Montpellier, Montpellier,
France; i Center for Autoinflammatory Diseases and Immunodeficiency, IRCCS Giannina
Gaslini, Genova; j Center of Medical Genetics and Primary Health Care, Yerevan,
Armenia; k Department of Medicine, Division of Respirology, Neurology and
Rheumatology, Kurume University School of Medicine, Kurume, Japan; l Department
of Dermatology, Wakayama Medical University, Wakayama, Japan; m Department of
Pediatrics and Child Health, Kurume University School of Medicine, Kurume,
Japan; n ViennaLab Diagnostics, Vienna, Austria; o Amyloidosis Research and Treatment
Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; p Department of Applied
Genomics, Kazusa DNA Research Institute, Kisarazu, Japan; q Department of Pediatrics,
Hacettepe University, Ankara, Turkey; r European Molecular Genetics Quality Network
(EMQN), Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester,
UK; s Department of Genetics, University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands; t Stem Cells, Cellular Plasticity, Regenerative
Medicine and Immunotherapies, INSERM, Montpellier, France.
* Address correspondence to this author at: Department of Genetics, University of
Groningen, University Medical Center Groningen, Groningen, The Netherlands. Fax
þ31 50 361 7231; E-mail m.e.van.gijn@umcg.nl.
† Should all be considered first authors.
‡Should both be considered last authors.
Received September 26, 2019; accepted January 8, 2020. DOI: 10.1093/clinchem/hvaa024
VC American Association for Clinical Chemistry 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-
nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and
that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
525









roningen user on 19 N
ovem
ber 2020
provided an insight into SAIDs physiopathology. A
common defect is dysregulation and/or overactivation of
intracellular pathways of innate immune cells (2).
Reliable diagnosis of SAIDs is crucial for early ac-
cess to treatment adapted to the underlying disease. As
disease manifestations may overlap, SAID diagnosis is
highly dependent on genetic testing. To this end, regis-
tries for patients with SAIDs (Eurofever) (3) and for
SAID gene variants (Infevers) (4) have been established.
In 2012, we developed specific recommendations for
the genetic testing and reporting of the 4 prototypic
HRFs: familial Mediterranean fever (FMF), MEFV
(Mediterranean FeVer) gene, MIM 608107, mevalonate
kinase deficiency (MKD), MVK (Mevalonate Kinase)
gene, MIM 251170, tumor necrosis factor (TNF) re-
ceptor-associated periodic syndrome (TRAPS),
TNFRSF1A (TNF receptor superfamily 1) gene, MIM
191190 and cryopyrin-associated periodic syndromes
(CAPS or NLRP3-AID), NLRP3 (NOD-like receptor
family, pyrin domain-containing 3) gene, MIM 606416
(5). The guidelines referred to the classical Mendelian
inheritance of HRFs, being either autosomal recessive
(FMF and MKD) or autosomal dominant (TRAPS and
NLRP3-AID) and to a limited number of variants
detected at that time, mainly by Sanger sequencing of
variant hotspots. Since then, with the advent of next-
generation sequencing (NGS), unexpected phenotypes,
nonclassical modes of inheritance, and postzygotic var-
iants were described in HRFs (6). This prompted a
reappraisal of the routine scope and interpretation of
HRFs genetic diagnosis.
We have incorporated several recent discoveries to
the current recommendations:
FMF, the typical phenotype associated with MEFV,
is caused by biallelic variants mainly located in exon 10
(encoding the pyrin B30.2 domain) (7, 8); however, a
substantial number of patients with FMF with only one
MEFV variant in exon 10 have been described (9).
Monoallelic substitutions in other exons can result in a
dominant and severe FMF-like phenotype; examples of
predicted changes at the (p.) protein level are:
p.(Pro373Leu) (exon 3), p.(His478Tyr) (exon 5) (10),
and p.(Thr577/Ser/Asn/Ala) amino acid changes (exon
8) (11). The corresponding complementary (c.) DNA
changes for these variants, and those cited in this special
report can all be found in the Infevers registry (4). In ad-
dition, new MEFV-associated phenotypes were reported.
Pyrin-associated autoinflammation with neutrophilic der-
matosis is another severe and dominantly inherited dis-
ease caused by missense variants in exon 2 substituting
the p.(Ser242) or p.(Glu244) residues (12). These var-
iants disrupt the phosphorylation-dependent binding of
pyrin with its endogenous inhibitor, the 14-3-3 protein.
All MEFV-associated phenotypes are now collectively
called pyrin-associated autoinflammatory diseases (13).
Several heterozygous, loss of function MVK variants
are associated with a rare dominant skin disorder of
adult onset called disseminated superficial actinic poro-
keratosis (DSAP), first described in the Chinese popula-
tion. A recent study demonstrated a second, postnatal
hit in the skin lesions of patients with DSAP rendering
epidermal cells biallelic for MVK mutations (14).
Patients with DSAP have no clinical features of MKD
and the MVK variants linked to DSAP are distributed
throughout the MVK gene. Interestingly, a search in the
Infevers registry retrieved 5 variants causing DSAP, i.e.,
p.(Gly140Argfs*47), p.(Gly212del), p.(Ser272Phe),
p.(Gly335Asp) and p. (Gly376Ser), which have also
been found in combination with a second loss of func-
tion MVK variant in patients with MKD.
Gene mosaicism resulting from postzygotic variants
in the NLRP3 gene accounts for up to 30% of NLRP3-
AID and NLRP3-AID-like patients in whom conven-
tional sequencing did not detect pathogenic variants
(15–17). Postzygotic pathogenic variants were initially
found in children with severe forms of NLRP3-AID
(15), subsequently in adult patients with typical, milder
NLRP3-AID (16).
Among other notable and recently documented
SAIDs-associated genes are adenosine deaminase 2
(ADA2), nucleotide-binding oligomerization domain-
containing protein (NOD2), proline-serine-threonine
phosphatase-interacting protein 1 (PSTPIP1), and the
tumor necrosis factor alpha-induced protein 3
(TNFAIP3) genes.
Deficiency of ADA2 (DADA2, MIM 615688) typ-
ically presents with systemic vasculitis, early onset poly-
arteritis nodosa, and stroke (18, 19). The age at onset
varies widely, and the spectrum of DADA2 continues to
expand to include hemorrhagic strokes, portal and sys-
temic hypertension, hematologic abnormalities, im-
mune deficiency, and bone marrow failure. Patients
with DADA2 have biallelic hypomorphic ADA2 var-
iants; more than 60 pathogenic variants described to
date are located over the entire ADA2 coding region.
Small and large deletions have also been reported, and
typically in combination with a missense variant on the
opposite ADA2 allele. The pathogenesis of DADA2
remains uncertain. However, protein function can be
assessed by a biochemical assay, which demonstrates low
or absent plasma ADA2 activity (20–22).
NOD2 is associated with 2 distinct diseases: the
rare dominantly inherited Blau syndrome and multifac-
torial inflammatory bowel diseases (IBD) (23–25). Blau
syndrome is typically characterized by a triad of nonca-
seating granulomatous inflammatory arthritis, uveitis,
and dermatitis. Most pathogenic variants causing Blau
syndrome localize in or near the central NOD domain
of the NOD2 protein; p.(Arg334Gln) and
p.(Arg334Trp) are the most frequent ones (26, 27). In
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addition, NOD2 mosaicism has recently been reported
in 4 unrelated patients with Blau syndrome (28). Early
onset sarcoidosis is considered a sporadic form of Blau
syndrome based on a similar phenotype and overlapping
pathogenic variants. By contrast, several common var-
iants including (p.(Arg702Trp), p.(Gly908Arg),
p.(Leu1007fs)) located in one of the C-terminal leucine-
rich repeats domain of the NOD2 protein have been
repeatedly identified susceptibility alleles for Crohn
disease. Up to 30% of patients with Crohn disease carry
one or 2 copies of these variants in NOD2 (25).
Pyogenic arthritis, pyoderma gangrenosum and
acne (PAPA, MIM 604416) syndrome is caused by het-
erozygous missense PSTPIP1 variants, predominantly
p.(Ala230Thr) and p.(Glu250Gln), that reside in the
protein’s F-BAR domain (29). PSTPIP1 interacts with
pyrin. The mutant protein is hyperphosphorylated and
binds more strongly to pyrin, provoking interleukin-1b
over-production. Another phenotype, the PSTPIP1-
associated myeloid-related proteinemia inflammatory
syndrome, characterized by neutropenia and markedly
high myeloid-related protein 8/14 (calprotectin) con-
centrations with accumulation of zinc, has been linked
to the p.(Glu250Lys) and p.(Glu257Lys) substitutions
(30). Missense variants in the C-terminal domain of
PSTPIP1 may be risk factors for pyoderma gangreno-
sum, acne, and suppurative hidradenitis syndrome (31).
Heterozygous variants in the TNFAIP3 gene cause
haploinsufficiency of A20 (HA20, MIM 616744) (32).
These patients present in childhood with fever, ulceration
of mucosal surfaces, particularly in oral, genital, and gas-
trointestinal areas. Other disease features include skin
rash, uveitis, polyarthritis, and a spectrum of autoimmune
manifestations. Dominance in HA20 is attributed to in-
sufficient concentrations of the A20 protein. The most
frequent pathogenic genetic alterations found in HA20
are heterozygous frameshift, nonsense variants, and dele-
tions, which disrupt the ubiquitin-editing activity of A20
on nuclear factor kappa B (NF-kB) regulatory proteins
and prolong NF-kB induced inflammation. Substitutions
such as p. Cys243Tyr resulting in increased production of
human inflammatory cytokines by reduced suppression of
NF-jB activation have also been described (33) while sev-
eral common TNFAIP3 substitutions (allele
frequency> 0.1) are risk factors for autoimmune condi-
tions (rheumatoid arthritis, systemic lupus erythematosus,
or Sjogren associated non-Hodgkin lymphoma).
The recent discoveries of new SAIDs, pathogenic
copy-number variations (CNV) (34, 35) and low fre-
quency gene mosaicism (19), along with the possibility
of simultaneous screening of multiple genes using NGS-
based methods provided genetic characterization of
many previously undiagnosed patients. Conversely, one
noticeable growing difficulty generated by large scale se-
quencing approaches is the expanding number of
patients with variants of unknown significance and or
common variants in multiple genes, resulting in ambig-
uous or misleading conclusions. Among them are the
terms “reduced penetrance,” which concern monogenic
diseases, and “risk factors,” which concern multifactorial
diseases. At-risk variants are associated with broader
phenotypes spectrum and often with a higher overall
population frequency than likely pathogenic variants.
We therefore revised and updated the 2012 guidelines
to comply with novel data generated by high through-
put sequencing technologies and extended them with
the 4 genes aforementioned as causing monogenic
SAIDs (DADA2, Blau syndrome, PAPA, HA20).
Materials and Methods
Establishing these guidelines necessitated several prepa-
ratory steps, which are summarized in Fig. 1.
INITIAL MEETING
A first meeting was held during the European Society of
Human Genetics 2018 conference (Milano, Italy) to
identify elements to update, plan the new draft, and as-
semble critical data. Attendees were predominantly
geneticists.
SURVEYS
Two parallel surveys were employed. The first survey
aimed at selecting new SAIDs-associated genes to in-
clude in these guidelines. An exhaustive list of SAID
genes available in Infevers was circulated by E-mail to
relevant laboratories retrieved from Orphanet, Infevers
contributors and participants of the European
Molecular Genetics Quality Network (EMQN) HRF
scheme. Laboratories were asked to select genes rou-
tinely included in their sequencing panels. This survey
revealed a core list of 19 genes from which the writing
group selected ADA2, NOD2, PSTPIP1, and TNFAIP3
based on the following criteria: number of papers and
functional assays available, large number of sequence
variants reported, and individual requests received by
members of the writing group. Four additional genes
were considered a reasonable number to manage.
A second survey was developed to highlight current
genetic practices in genetic testing of SAIDs as a basis to
elaborate guidelines suitable for all laboratories. Six
queries were defined and their answers summarized by
Rowczenio et al. (36).
SCORING OF NEW GENETIC VARIANTS
We assigned pathogenicity scores (5¼ Pathogenic,
4¼Likely pathogenic, 3¼Variant of uncertain signifi-
cance (VUS), 2. Likely Benign, and 1. Benign) for var-
iants of the ADA2, NOD2, PSTPIP1, and TNFAIP3
genes using an original workflow we developed for the
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HRF genes (37). In brief, data available in Infevers were
downloaded, and the variants were scored by IC, DR,
YS, IT, and MvG. The classification fulfilled the
American College of Medical Genetics and Genomics
recommendations and integrated data from both reports
and the experts’ own unpublished studies. A classifica-
tion was considered validated if 75% of the experts
reached consistent votes. A provisional classification was
assigned if between >50% and 75% of experts reached
consistent votes. Consensus was reached after sequential
rounds of voting. The experts could reach a similar clas-
sification while relying on different combinations of
American College of Medical Genetics and Genomics
classification items. Converging the experts’ opinion at
the classification level rapidly enhanced the consensus
classification. Pathogenicity scores with their respective
status were then made available in Infevers.
ISSUING OF THE NEW GUIDELINES
A writing group including organizers and assessors of
the European Molecular Genetics Quality Network
(EMQN) HRFs scheme (YS, IC, DR, MvG and IT)
drafted the first version of the guidelines. The draft
was disseminated to molecular geneticists and clinicians
working in the field of SAIDs, then discussed in a work-
shop held during the ISSAID 2019 conference (Genoa,
Italy). A second amended version was disseminated by
e-mail, after which the final document was ratified.
Results and Recommendations
WHERE TO REQUEST A GENETIC TEST FOR SAIDs?
SAIDs genetic testing is available in generalist and ex-
pert laboratories, dedicated medical reference centers,
and networks, formally nominated or recognized in sev-
eral countries (France, Italy, Spain, UK, Germany,
Turkey, Israel, USA, Armenia, Japan, and the
Netherlands). In 2019, for example, 147 laboratories of-
fered FMF genetic testing worldwide, and 62 of them
participated in an HRF specific external genetic quality
assessment and proficiency scheme provided by EMQN
(online Supplemental Information file). Laboratory
Fig. 1. The workflow of retrieval and assembly of best practice guidelines for the genetic diagnosis of autoinflammatory dis-
eases. Two physical meetings, two surveys, and several rounds of sequence variant scoring were necessary. ESHG, European
Society of Human Genetics; ISSAID, International Society of Systemic Autoinflammatory Diseases; ADA2, adenosine deami-
nase 2; NOD2, Nucleotide binding oligomerization domain containing 2; PSTPIP1, Proline-serine-threonine phosphatase
interacting protein 1; TNFAIP3, TNF alpha induced protein 3.
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certification data is available at Orphanet and the NCBI
genetic testing registry.
WHEN TO REQUEST A GENETIC TEST FOR SAIDs?
Most laboratories currently do not have specific adminis-
trative prerequisites for genetic testing apart from legal
ones, i.e., medical prescription and informed consent
(36). Laboratory geneticists appreciate inclusion of medi-
cal information at referral but do not necessarily consider
it mandatory to perform genetic analysis. Interaction be-
tween clinicians and laboratory geneticists is mandatory
(Supplemental document); we suggest the following:
Patients with overt disease. Clinical data documenting
the SAID phenotype and, where available, defining spe-
cific manifestations or the fulfillment of clinical criteria
should be provided for better diagnostic orientation,
choice of the sequencing strategy and interpretation of
the genetic results. To limit the workload for clinicians,
we suggest that laboratories request a minimal core of
items (online Supplemental Table 1).
Predictive diagnosis. In the context of a familial situation,
even equivocal symptoms should suggest genetic testing,
since both the genetic and environmental backgrounds
may reduce the expressivity of the familial genotype. For
diseases with risk of irreversible damage such as severe
NLRP3-AID (risk of central nervous system lesions or
AA-type amyloidosis) or DADA2 (risk of stroke), pre-
dictive testing of asymptomatic individuals may be justi-
fied and should be discussed in a multidisciplinary team
of experts. Follow-up of at-risk individuals may avoid
occurrence of life-threatening complications (for exam-
ple, renal amyloidosis by monitoring serum amyloid A
or urinalysis). However, whether such cases should be
given prophylactic treatment remains controversial.
Prenatal diagnosis. We do not recommend prenatal or
preimplantation genetic diagnosis in families without a
history of deleterious SAIDs, as inconclusive genetic
results in case of reduced penetrance genotypes or novel
VUS may create unnecessary anxiety. In addition, most
SAID conditions considered here are successfully treatable,
and symptoms may subdue over time. In the case of dele-
terious diseases, genetic counseling should always precede
prenatal diagnosis or preimplantation genetic diagnosis.
HOW TO CHOOSE THE BEST DIAGNOSTIC STRATEGY?
Elements collected through the prerequisite form (on-
line Supplemental Table 1) may orient the testing strat-
egy. However, for those patients presenting with general
or atypical SAID features, selecting a genetic screen may
be very challenging and is dictated in part by the meth-
odologies available in the laboratory.
Test methods and scope. Both Sanger and NGS sequenc-
ing are in use in most laboratories providing genetic di-
agnosis of SAIDs (36). Sequencing of a specific gene
(Sanger or NGS) is advised when clinical criteria apply
or a biochemical test is positive (e.g., decreased MVK or
ADA2 activity); A limited initial MEFV exon 10 se-
quencing is highly recommended for FMF diagnosis,
however using an NGS gene panel is preferable in other
cases. We suggest sequencing the 8 genes at a minimum,
and if possible additional SAID genes from the list refer-
enced in Infevers (which is constantly updated).
Information on assessing genetic performance is avail-
able in the online Supplemental Information file. We
do not yet recommend both exome sequencing and ge-
nome sequencing in routine settings, but these can be
selectively applied to patients whose gene panels are not
informative.
Complementary approaches. Given the growing number
of pathogenic CNVs (34, 35, 38) or postzygotic variants
found in SAID-associated genes (15–17), we recom-
mend mosaicism detection and that implementation of
CNV detection approaches be added to the routine
diagnostics in those patients with no confirmatory geno-
type obtained with strategies that do not allow for CNV
or mosaicism detection. Chromosomal imbalances in-
volving either loss or gain of large genomic regions may
be detectable with molecular cytogenetic techniques
such as comparative genomic hybridization or single nu-
cleotide polymorphism arrays. Validation of small rear-
rangements by a second method, such as quantitative
PCR (qPCR or real-time PCR) is advisable. Multiplex
ligation-dependent probe amplification analysis, long-
range PCR and long read sequencing can also prove
helpful to detect smaller CNVs. Quantitative RT–PCR
can be used to search for alterations in gene expression,
in case other DNA-based confirmatory methods are not
available.
Gene mosaicism can be detected (or validated) with
other NGS technologies such as single molecule molecu-
lar inversion probes or amplicon-based deep sequencing.
Optimal strategy at a glance. Online Supplemental Table
2 summarizes an optimal strategy for identifying and
validating a pathogenic variant in each gene. Figure 2
shows a decision tree for genetic diagnosis of the 8 genes
described in this special report, based on the patient’s
medical referral.
HOW TO INTERPRET THE GENETIC TEST?
Classification and validation of sequence variants
identified in SAID-associated genes. We recommend to
use an approach which considers a range of evidence for
the classification of variants, e.g., the American College
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of Medical Genetics and Genomics guidelines (39). An
expert consensus interpretation of about 1300 sequence
variants for the 8 selected genes relying on both public
and unpublished, lab generated data (Supplemental
Table 3 and Supplemental document) is available at the
Infevers website. For the final consensus score, we used
the rules previously described (37), and in the Materials
and Methods section. Online Supplemental Table 3
demonstrates the progression made by the current work
for variants listed in Clinvar, compared to the data from
computational tools for semi-automated variant inter-
pretation and to the classification made by geneticists
experienced in SAIDs and EMQN. Of note,
classifications, especially VUS, may change when more
information on function and regulation of aberrant pro-
teins becomes available.
De novo and postzygotic variants. De novo variants, occa-
sionally generated by a postzygotic mutational event
during embryonic development or the lifespan, may
cause dominantly inherited SAIDs in sporadic cases
(17). Pathogenic postzygotic variants are predominantly
present in the myeloid cells, which are the main effector
cells in SAIDs. Pathogenicity of a new variant should be
assigned based on a well-defined phenotype and func-
tional assays are suggested, although typically performed
Fig. 2. Decision tree to select the optimal methodological strategy for the genetic diagnosis of 8 autoinflammatory diseases.
Different strategies are used worldwide depending on local use and equipment availability. This general scheme suggests either
an “all-in-one” approach, if the NGS strategy used allows for mosaicism and CNV detection, or sequential steps for variant detec-
tion in 8 genes responsible for NGS. Green boxes: recommended if prerequisites met or in an emergency; Yellow boxes: NGS-
based approaches preferable (to check all exons, mosaicism, CNV, other genes) when phenotypes are not discriminating enough
and functional test are not available for these diseases; Orange boxes: Sanger not recommended (mosaicism not detected).
Asterisk, if available. Dotted line: better after a multidisciplinary decision. ESHG, European Society of Human Genetics; ISSAID,
International Society of Systemic Autoinflammatory Diseases; FMF, familial Mediterranean fever; SAID, systemic autoinflamma-
tory diseases; DADA2, Deficiency of ADA2; HA20, Haploinsufficiency of A20; MKD, mevalonate kinase deficiency; CAPS, cryo-
pyrin-associated periodic syndromes; PAPA/PAMI, pyogenic arthritis, pyoderma gangrenosum and acne, PSTPIP1-associated
myeloid-related proteinemia inflammatory; TRAPS, TNF receptor-associated periodic syndrome.
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in research laboratories. Follow-up on its possible germ-
line transmission is advised (online Supplemental
Information file).
Geographic and ethnic considerations. Studies of disease
expressivity in ethnically matched FMF patients have in-
dicated that Western world geography and/or environ-
mental factors may reduce FMF disease severity,
possibly by epigenetic mechanisms (40). Therefore, ge-
notype–phenotype correlations should be reassessed
regionally.
Confirmation of clinical diagnosis. Confirmation of a
dominant disease requires identification of a pathogenic
or likely pathogenic variant. Confirmation of a recessive
disease requires 2 pathogenic or likely pathogenic var-
iants in trans phase. We strongly recommend parental
testing for this purpose. A combination in trans of a
pathogenic or likely pathogenic variant with a rare or
novel VUS should be reported as consistent with the
clinical disease diagnosis. Identification of the de novo
nature of a variant may further support its pathogenic-
ity. A genotype including a common VUS (often found
in patients with SAID that do not exhibit a typical phe-
notype for the disease) should not be regarded as confir-
matory. A broader screen of genes may identify the
responsible pathogenic variant in another autoinflam-
matory gene. Table 1 provides detailed recommenda-
tions for genotype interpretation.
HOW TO REPORT GENETIC RESULTS?
We suggest only reporting rare class 3, class 4, and class
5 variants. Table 1 displays examples of reporting these
variants in the context of phenotype. When the diagno-
sis is not confirmed at the genetic level, the report
should state that the diagnosis relies on clinical judg-
ment or criteria.
Descriptions of autoinflammatory manifestations in
patients heterozygous for classically recessive diseases
such as FMF are becoming more frequent (6).
However, the genetic laboratory report should not state
automatically that the diagnosis is consistent with pyrin-
associated autoinflammatory diseases. This statement
should be restricted to certain pathogenic variants lo-
cated outside exon 10, such as variants in codons 242,
244, 373, 478, or 577, along with a comment on the
consistency with the patient’s phenotype and familial
segregation if available. In some populations where high
carrier rates due to a founder effect are encountered
(e.g., M694V in the MEFV gene in individuals of
Mediterranean descent), NGS panels can detect the
concomitant presence of heterozygous pathogenic var-
iants in SAID genes other than those identified as causal
(based on the phenotype and genotype). These variants
should be interpreted cautiously. We suggest consider-
ing them at best as possible modifier alleles when they
converge into the same inflammatory pathway as the
confirmed genetic disease.
Discussion
In 2012, we proposed a consensus set of best practice
guidelines for genetic testing of a selection of 4 HRFs
aimed at improving the quality of their molecular diag-
nostics, and for promoting harmonization and standard-
ization of laboratory test reports (5). As the field of
SAIDs has been steadily evolving with the discovery of
novel genes and sequence variants, novel modes of in-
heritance, and increased genetic and allelic heterogene-
ity, we have now extended the routine diagnosis to
include new SAID-associated genes, and have revised
the guidelines to include newer NGS approaches.
Online Supplemental Table 4 summarizes the evidences
for recommendation grading, and online Supplemental
Table 5 summarizes what has changed and improved
since 2012.
Finally, we anticipate several future challenges for
genetic diagnosis of SAIDs that will require continuous
re-assessment of genetic guidelines and classification
criteria. A number of recently identified SAID-
associated genes still lack substantial databases and
guidelines due to the rarity of disease-associated variants
in these genes. Because NGS-based sequencing plat-
forms are now widely used in many countries, the ex-
tensive sequencing will ultimately identify a higher
number of new sequence variants in any given patient,
challenging their expert interpretation. Epigenetic risk
factors and modifiers will also be identified and need to
be incorporated in SAID diagnosis. These challenges
will only be met by collaborative efforts and interna-
tional cohort studies. We believe the guidelines pro-
posed here will be of immediate help to the SAID
medical community and the practice of precision
medicine.
Supplemental Material
Supplemental material is available at Clinical Chemistry
online.
Nonstandard Abbreviations: EMQN, European Molecular Genetics
Quality Network; ISSAID, International Society for Systemic
Autoinflammatory Diseases; SAID, systemic autoinflammatory dis-
eases; HRF, hereditary recurrent fevers; NGS, Next-Generation
Sequencing; MIM, Mendelian inheritance in men; PAAND, pyrin-as-
sociated autoinflammation with neutrophilic dermatosis; DSAP, dis-
seminated superficial actinic porokeratosis; DADA2, deficiency of
ADA2; CNV, copy-number variations; HA20, haploinsufficiency of
A20; VUS, variant of uncertain significance.
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List of Genes: ADA2, adenosine deaminase 2; MEFV, Mediterranean
fever, TNFRSF1A, TNF receptor super family 1A; MVK, mevalonate
kinase; NLRP3, NLR family pyrin domain-containing 3; NOD2, nu-
cleotide-binding oligomerization domain-containing 2; PSTPIP1, pro-
line-serine-threonine phosphatase-interacting protein 1; TNFAIP3,
TNF alpha-induced protein 3.
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